A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability




TekijätKopra Kari, Valtonen Salla, Mahran Randa, Kapp Jonas N, Hassan Nazia, Gillette William, Dennis Bryce, Li Lianbo, Westover Kenneth D, Plückthun Andreas, Härmä Harri

KustantajaMDPI

Julkaisuvuosi2022

JournalInternational Journal of Molecular Sciences

Tietokannassa oleva lehden nimiINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lehden akronyymiINT J MOL SCI

Artikkelin numero 7095

Vuosikerta23

Numero13

Sivujen määrä16

DOIhttps://doi.org/10.3390/ijms23137095

Verkko-osoitehttps://www.mdpi.com/1422-0067/23/13/7095

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/175932873


Tiivistelmä
Thermal unfolding methods are commonly used as a predictive technique by tracking the protein's physical properties. Inherent protein thermal stability and unfolding profiles of biotherapeutics can help to screen or study potential drugs and to find stabilizing or destabilizing conditions. Differential scanning calorimetry (DSC) is a 'Gold Standard' for thermal stability assays (TSA), but there are also a multitude of other methodologies, such as differential scanning fluorimetry (DSF). The use of an external probe increases the assay throughput, making it more suitable for screening studies, but the current methodologies suffer from relatively low sensitivity. While DSF is an effective tool for screening, interpretation and comparison of the results is often complicated. To overcome these challenges, we compared three thermal stability probes in small GTPase stability studies: SYPRO Orange, 8-anilino-1-naphthalenesulfonic acid (ANS), and the Protein-Probe. We studied mainly KRAS, as a proof of principle to obtain biochemical knowledge through TSA profiles. We showed that the Protein-Probe can work at lower concentration than the other dyes, and its sensitivity enables effective studies with non-covalent and covalent drugs at the nanomolar level. Using examples, we describe the parameters, which must be taken into account when characterizing the effect of drug candidates, of both small molecules and Designed Ankyrin Repeat Proteins.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 17:58